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Abstract
Background: Recent in-vitro studies have suggested that mast cells are involved in Dengue virus infection. To clarify the role
of mast cells in the development of clinical Dengue fever, we compared the plasma levels of several mast cell-derived
mediators (vascular endothelial cell growth factor [VEGF], soluble VEGF receptors [sVEGFRs], tryptase, and chymase) and -
related cytokines (IL-4, -9, and -17) between patients with differing severity of Dengue fever and healthy controls.
Methodology/Principal Findings: The study was performed at Children’s Hospital No. 2, Ho Chi Minh City, and Vinh
Long Province Hospital, Vietnam from 2002 to 2005. Study patients included 103 with Dengue fever (DF), Dengue
hemorrhagic fever (DHF), and Dengue shock syndrome (DSS), as diagnosed by the World Health Organization criteria. There
were 189 healthy subjects, and 19 febrile illness patients of the same Kinh ethnicity. The levels of mast cell-derived
mediators and -related cytokines in plasma were measured by ELISA. VEGF and sVEGFR-1 levels were significantly increased
in DHF and DSS compared with those of DF and controls, whereas sVEGFR-2 levels were significantly decreased in DHF and
DSS. Significant increases in tryptase and chymase levels, which were accompanied by high IL-9 and -17 concentrations,
were detected in DHF and DSS patients. By day 4 of admission, VEGF, sVEGFRs, and proteases levels had returned to similar
levels as DF and controls. In-vitro VEGF production by mast cells was examined in KU812 and HMC-1 cells, and was found to
be highest when the cells were inoculated with Dengue virus and human Dengue virus-immune serum in the presence of
IL-9.
Conclusions: As mast cells are an important source of VEGF, tryptase, and chymase, our findings suggest that mast cell
activation and mast cell-derived mediators participate in the development of DHF. The two proteases, particularly chymase,
might serve as good predictive markers of Dengue disease severity.
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Introduction
Dengue virus infection is associated with disease, ranging from
Dengue fever (DF) to Dengue hemorrhagic fever (DHF) and/or
Dengue shock syndrome (DSS). As severe diseases typically
develop in individuals suffering secondary Dengue virus infection,
host immunological factors appear to play a role in DHF and DSS
[1]. DHF and DSS are characterized by increased vascular
permeability and hemorrhagic manifestations [2], with the former
phenotype recognized as the hallmark of these severe forms of
Dengue. However, the cellular factors and immune molecules
underling the development of DHF and DSS are not well
understood.
Recent studies on Dengue virus infection have demonstrated
that the serum levels of vascular endothelial cell growth factor
(VEGF)-A (formerly VEGF) are elevated in DHF patients [3].
VEGF/vascular permeability factor (VPF) was first identified and
characterized as a potent stimulator of endothelial permeability
[4], and was shown to increase vascular permeability 50,000 fold
more efficiently than histamine [5]. VEGF was subsequently
reported to promote the proliferation, migration, and survival of
endothelial cells [6]. VEGF is a member of a growing family of
related proteins that includes VEGF-B, -C, -D, and placental
growth factor [7]. A potential candidate for the VEGF-binding
molecule is the soluble form of its receptor. At least two types of
VEGF receptors are expressed on endothelial cells; both are
www.plosntds.org 1 February 2012 | Volume 6 | Issue 2 | e1505transmembrane receptor tyrosine kinases, namely, VEGFR-1 or
Fms-like tyrosine kinase 1 (Flt-1), and VEGFR-2 or kinase insert
domain receptor (KDR) [8]. VEGFR-1 is expressed on monocyte-
macrophage lineages other than endothelial cells, whereas VEGFR-
2 is expressed primarily on endothelial cells and their progenitors
[9,10]. In addition to its role in promoting endothelial permeability
and proliferation, VEGF may contribute to inflammation and
coagulation. For example, under in-vitro conditions, VEGF induces
the expression of several types of cell adhesion molecules, including
E-selectin, intercellular adhesion molecule 1 (ICAM-1), and
vascular cell adhesion molecule 1 (VCAM-1), in endothelial cells
and promotes the adhesion of leukocytes [11,12]. Moreover, VEGF
signaling up-regulates tissue factor mRNA expression, and protein
and procoagulant activities [13]. The proinflammatory/procoagu-
lant effects of VEGF are mediated, at least in part, by the activation
of the transcription factors NF-kB, Egr-1, and NFAT. VEGF has
been implicated as a pathophysiological mediator in several human
disease states, including rheumatoid arthritis, cancer, and inflam-
matory bowel disease [14–16].
Dengue patients typically exhibit increased levels of urinary
histamine, which is a major granule product of mast cells and
whose levels correlate with disease severity [17]. A large autopsy
study of 100 DHF cases from Thailand found that mast cells in
connective tissue around the thymus exhibited swelling, cytoplas-
mic vacuolation, and loss of granule integrity, which are suggestive
of mast cell activation [18]. Although recent in-vitro studies have
also reported the involvement of mast cells in Dengue virus
infection [19,20], the potential role of mast cells in severe Dengue
disease has not yet been explored.
The activation of mast cells, which reside mainly in tissues and
are associated closely with blood vessels and nerves [21,22], is
tightly linked with local increases in vascular permeability in
allergic disease. Mast cells are key effector cells in IgE-dependent
immune responses, such as those involved in the pathogenesis of
allergic disorders or in certain instances of immunity to parasites
[23]. Recent works have revealed another aspect of mast cell
effector function, and mast cells play important roles in
inflammation and host defenses against foreign pathogens [24,25].
Mast cells synthesize and release a range of biologically active
substances, including proteases, biogenic amines, cytokines,
chemokines, and lipid mediators [26]. Mast cell proteases are
key protein components of secretory mast cell granules and are
essential for innate antimicrobial inflammatory responses [27–29].
It is estimated that mast cell proteases account for .25% of total
mast cell protein [30] and that human skin mast cells contain a
total of ,16 mg tryptase and chymase per 10
6 cells [31]. Mast cell
proteases, tryptase, and chymase are serine proteases with trypsin-
or chymotrypsin-like substrate specificities, and are the major
proteins stored and secreted by mast cells. Measurement of the
serum (or plasma) levels of these proteases are recommended in
the diagnostic evaluation of systemic anaphylaxis and mastocyto-
sis, with total tryptase levels generally reflecting either the
increased burden of mast cells in patients with all forms of
systemic mastocytosis, or the decreased burden of mast cells
associated with cytoreductive therapies in these disorders.
Tryptase and chymase levels generally reflect the magnitude of
mast cell activation and are typically elevated during systemic
anaphylaxis. Secreted tryptase and chymase promote inflamma-
tion, matrix destruction, and tissue remodeling by several
mechanisms, including the destruction of procoagulant, matrix,
growth, and differentiation factors, and the activation of
proteinase-activated receptors, urokinase, metalloproteinases, and
angiotensin. In addition, these two serine proteases also modulate
immune responses by hydrolyzing chemokines and cytokines, and
can also suppress inflammation by inactivating allergens and
neuropeptides responsible for inflammation and bronchoconstric-
tion. Thus, similar to mast cells themselves, mast cell serine
proteases play multiple roles in host defenses, which may be either
beneficial or harmful depending on the specific conditions. As
substantial levels of tryptase and chymase are only found in mast
cells, these proteases are considered to be selective markers of mast
cell activation [26]. The importance of cytokines and chemokines
together with mast cells in the pathogenesis of Dengue virus
infection has been demonstrated [19,20], however, the roles of the
mast cell-specific proteases, tryptase and chymase, remain unclear.
Here, to determine the roles of mast cells and mast cell-derived
mediators in DHF and DSS, we first measured the levels of VEGF,
soluble forms of VEGFR-1 and -2, tryptase, and chymase in the
plasma of Dengue patients and healthy control subjects.
Moreover, because IL-9 has been reported as a T cell-derived
growth factor of mast cells [32–34] and more recently has been
implicated as a Th17-derived cytokine that contributes to
inflammatory diseases, the involvement of IL-9 and IL-17 in
Dengue infection was also investigated.
Methods
Study population and Dengue classification
The study was performed at two hospitals, Children’s Hospital
No. 2 in Ho Chi Minh City (HCMC) and the Center for
Preventive Medicine in Vinh Long Province (VL), Vietnam. The
enrolment was a consecutive sequence of hospitalized children at
each hospital. The inclusion criteria on admission to the hospital
were age (6 months to 15 years old) and ethnicity (Kinh race). A
total of 103 subjects from HCMC and VL were enrolled in this
study during 2002–2005 (Table 1). The patients were suspected to
have Dengue virus infection based on clinical symptoms at
admission. After hospitalization, the patients were diagnosed using
standardized serology techniques, as described below, and the
WHO (1997) classification criteria for Dengue virus infection [35].
It was reported that the sensitivity of WHO criteria for DSS in
Vietnam was only 82%, mainly due to the lack of evidence for
Author Summary
To clarify the involvement of mast cells in the develop-
ment of severe Dengue diseases, plasma levels of mast
cell-derived mediators, namely vascular endothelial cell
growth factor (VEGF), tryptase, and chymase, were
estimated in Dengue patients and control subjects in
Vietnam. The levels of the mediators were significantly
increased in Dengue hemorrhagic fever (DHF) and Dengue
shock syndrome (DSS) patients compared with those of
Dengue fever (DF) and control (febrile illness and healthy
subjects) patients, and the soluble form of VEGF receptors
(sVEGFR)-1 and -2 levels were significantly changed in the
patients with severe disease. After 2–4 days of admission,
the mediator levels had returned to similar levels as those
of DF and control subjects. Furthermore, the levels of the
Th17 cell-derived mast-cell activators IL-9 and -17 were
increased in DHF and DSS. In-vitro production of VEGF in
human mast cells was significantly enhanced in the
presence of IL-9 when these cells were inoculated with
Dengue virus in the presence of human Dengue virus-
immune serum. As mast cells are an important source of
VEGF, and tryptase and chymase are considered to be
specific markers for mast cell activation, mast cells and
mast cell-derived mediators might participate in the
development of DHF/DSS.
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WHO criteria, but included patients lacking a significant
reduction of platelet count, which accounted for no more than
11% of all DHF/DSS cases. Our classification scheme met the
requirements of the simplified Integrated Management of
Childhood Illness (IMCI) classification system, which is based on
plasma leakage as a hallmark of severe dengue disease (DHF/DSS)
[37].
Plasma samples were obtained from the 19 DF, 43 DHF,
and 41 DSS patients on the day of admission, and an addi-
tional 189 plasma samples from healthy, unrelated school
children living in HCMC and VL who had no symptoms of
Dengue virus infection were collected as control samples.
Eighteen (male: 12, female: 6) plasma samples were also col-
lected from school children with a febrile illness (38.960.9uC:
mean6SD) without an obvious source of infection, including
Dengue virus.
This study was approved by the institutional ethical review
committees of the Institute of Tropical Medicine, Nagasaki
University, Jikei University School of Medicine in Tokyo, and
the Pasteur Institute in Ho Chi Minh City. Written informed
consent was obtained from the parents or legal guardians of the
subjects upon enrollment.
Sample collection and serological diagnosis
The sample collection and serological diagnosis performed in
this cohort study were identical to those reported in our previous
study [38]. Blood samples were collected from patients with
suspected Dengue infection at the time of admission (day 0) and
twice during the following four days (days 2 and 4). Plasma
samples were used for the titration of anti-Dengue virus IgM and
IgG antibodies, virus isolation, and RT-PCR for the determina-
tion of viral serotype. Dengue virus infection was determined by
previously established serologic criteria for IgM/IgG ELISAs to
Dengue virus (DEN 1–4) and Japanese encephalitis virus in paired
plasma, collected with at least three-day intervals [39]. IgM and
IgG ELISAs were performed using kits obtained from the Pasteur
Institute, HCMC and were considered positive if the ratio of
optical density (OD) of test sera to the OD of negative control
plasma was $2.3 [35]. The cases were diagnosed as secondary
infection when the DV IgM-to-IgG ratio was ,1.8 [40].
Dengue virus serotyping was performed as previously reported
[38]. Briefly, acute plasma samples were used to inoculate C6/36
(Aedes albopictus) cells, virus was obtained, and the Dengue virus
serotype was then identified using either a direct or indirect
fluorescent antibody technique with monoclonal antibodies
supplied by the Centers for Disease Control and Prevention (Fort
Collins, CO, USA) [41]. Viral RNA was also extracted from the
acute plasma samples with the QIAamp Viral RNA Mini Kit
(Qiagen, Hilden, Germany) for the molecular detection of Dengue
virus and confirmation of its serotype, as previously described [41].
Briefly, cDNA from the Dengue virus genome RNA was amplified
with the Ready-to-go RT-PCR test kit (Amersham, MA, USA)
using a consensus primer set (D1 and D2) [31]. The serotype was
then determined by semi-nested PCR using specific primer sets
(TS1, TS2, TS3, and TS4) to amplify serotype-specific fragments
from the regions encoding the capsid and membrane proteins of
Dengue virus [39].
ELISA assay
The plasma levels of VEGF (VEGF-A), sVEGFR-1, sVEGFR-
2, IL-9, and IL-17 in samples from Dengue patient (DF, DHF, and
DSS) and control groups (febrile illness and healthy subjects) were
measured by ELISA kits (R&D Systems, Minneapolis, MN, or
Peprotech Inc., Rocky Hill, NJ). The levels of tryptase or chymase
in plasma from the Dengue patients and control groups, and the
culture supernatants of mast cells were examined by ELISA kits
(CSB, Newark, ED or Otsuka Pharmaceutical Co., Tokushima,
Japan).
Dengue virus infection and in-vitro production of VEGF
The human mast cell/basophil line KU812 [42] and human
mast cell line HMC-1 [43] were maintained in RPMI 1640
medium or IMDM (Invitrogen, Grand Island, NY). In the
infection experiments, Dengue virus 2 (DV16681 strain) was
propagated in the C6/36 cell line, and virus titers were then
determined by plaque assay using BHK-21 cells [44]. In control
experiments, the virus was rendered nonreplicative by placing a
sample aliquot under a germicidal lamp (125 mJ/10 min, UV
irradiation at 254 nm) at a distance of 5–6 cm, followed by a 30-
min incubation on ice [44]. For infection, HMC-1 or KU812 cell
pellets were adsorbed at 4uC for 90 min with aliquots of Dengue
virus or UV-inactivated virus, Dengue virus in combination with
human dengue virus immune serum (1:1,000 or 1:10,000 final
dilution), UV-inactivated virus in combination with human
dengue virus immune serum (1:1,000 or 1:10,000 final dilution),
or Dengue virus in combination with normal human serum
(1:1,000 final dilution) (premixed at 4uC for 90 min). Dengue virus
Table 1. Characteristics of the Dengue patients.
Characteristic DF (n=19) DHF (n=43) DSS (n=41)
Sex (Male: Female) 12:7 22:21 21:20
Fever (mean6SD uC) 37.960.7 39.260.7 39.160.8
Primary infection 9 11 10
Secondary infection 10 32 31
Dengue Virus 1 1 16 4
Dengue Virus 2 1 14 6
Dengue Virus 3 2 4 0
Dengue Virus 4 0 0 0
Dengue Virus (-) 15 9 31
Conjunctive bleeding 0 0 1
Subcutaneous bleeding 0 39 40
GI bleeding* 0 0 5
Plasma leakage signs** 0 0 11
Hematocrit 0 43 41
Thrombocytopenia 0 43 41
Hepatomegaly 0 11 32
Narrow blood pressure 0 0 23
Neurologic disorder 0 0 1
Shock 0 0 41
Dengue classification was performed according to the definitions of the World
Health Organization (WHO) [27]. DHF classification required fever or a history of
acute fever, bleeding manifestation, and signs of plasma leakage, which
included hemoconcentration, ascites, or pleural effusion with evidence of
thrombocytopenia. DSS classification required DHF manifestation plus evidence
of clinical hypovolemic shock. Cases of Dengue were confirmed by Dengue
virus RNA detection by RT-PCR and IgM antibody capture (MAC) ELISA in the
first or second paired samples. Dengue virus was isolated using plasma samples
collected between days 4–6. Primary or secondary infection was determined by
the AFRIMS method. Hct increase was determined by a .20% increase
compared with the normal range of the population. Thrombocytopenia was
defined as ,100,000 platelets/mm
3.
*GI bleeding: Gastrointestinal bleeding.
**Plasma leakage signs: Ascites and pleural effusion.
doi:10.1371/journal.pntd.0001505.t001
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enhancement of Dengue virus infection. Mast cells were infected at
a multiplicity of infection (MOI) of 3 plaque forming units (pfu)/
cell. Following adsorption, cells were washed and plated in 96-well
plates (0.25 mL/well) at 1610
6 cells/mL and then incubated at
37uCi n5 %C O 2 for 24 h. To examine the effects of IL-9 on the
production of VEGF from mast cells, mast cells treated with
Dengue virus and antibody were incubated with or without
recombinant human IL-9 (200 ng/mL, Peprotech, Rocky Hill,
NJ). Activation of mast cells with Compound (C) 48/80 (300 mg/
ml, Sigma-Aldrich, St. Louis, MO) was used as a positive control,
and the culture supernatant of C6/36 cells was used as a negative
control. For the measurement of VEGF levels in culture
supernatants, culture supernatants were collected from each well
after incubation and then stored at 280uC until being subjected to
ELISA.
Fluorescence microscopy
KU812 cells were inoculated with Dengue virus (MOI, 3) or
Dengue virus-antiserum combinations. After incubation for 24 h,
cells were fixed with 4% paraformaldehyde, washed, and then
permeabilized with 0.1% saponin for 1 h at room temperature.
Samples were then washed and incubated with mouse anti-
Dengue virus monoclonal antibody 1B7 [45] and isotype-matched
mouse IgG2a antibody (negative control, R&D Systems) on ice for
1 h, which were employed as primary antibodies. Subsequently,
samples were washed and incubated with FITC-labeled anti-
mouse IgG antibody (R&D Systems) for 1 h on ice. Cytospins
were made for each sample, and positive cells were observed by
fluorescence microscopy.
Statistical analysis
Plasma VEGF, sVEGFRs, IL-9, IL-17, tryptase, and chymase
levels were compared between the Dengue (DF, DHF, or DSS)
and control groups (febrile illness and healthy subjects) using the
unpaired Student’s t test. VEGF levels in the in-vitro experiments
were also compared between the Dengue virus infection and
control (UV-inactivated Dengue virus and Medium alone) samples
using the unpaired Student’s t test. A value of p,0.05 was
considered statistically significant.
Results
VEGF and sVEGFR levels in Dengue patients
As mast cells are an important source of VEGF [46,47], we first
measured VEGF levels in plasma samples from the DF (n=19),
DHF (n=43), and DSS (n=41) patient groups, and the control
group, which consisted of febrile illness and healthy subjects. On
day 0 (admission), the VEGF plasma levels were significantly
higher in DHF and DSS than those in DF, and febrile illness and
healthy subjects (Fig. 1A). The sVEGFR-1 levels in plasma were
higher in DSS than those in DF, DHF, febrile illness and healthy
subjects (Fig. 1B). In contrast with sVEGR-1, the levels of
sVEGFR-2 were dramatically decreased in DHF and DSS
compared with DF or febrile illness and healthy subjects (Fig. 1C).
We next examined the levels of VEGF and sVEGFRs in DHF
(n=21) and DSS (n=27) patients during the admission period
(Fig. 2). The VEGF levels in DHF and DSS, and sVEGFR-1 levels
in DSS were significantly higher than those of DF or healthy
controls on the day of admission (day 0); however, 2–4 days later
(convalescence), their levels had gradually declined to comparable
levels with DF, febrile illness, and healthy subjects by the
convalescent phase (day 4; VEGF DF: 0.616+0.24 ng/ml, febrile
illness: 0.5760.11 ng/ml, and healthy subjects: 0.5260.17 ng/ml;
sVEGFR-1 DF: 180.9+55.3 pg/ml, DHF: 223.66136 pg/ml,
febrile illness: 201.36167.1 pg/ml, and healthy subjects:
195.1659.1 pg/ml). The plasma levels of sVEGFR-2 in DHF
and DSS patients were significantly lower compared to those of
DF, febrile illness, and healthy subjects; however, the levels were
comparable between these groups by day 4 (Fig. 2). Taken
together, these findings suggested the possibility that VEGF and
sVEGFRs participated in severe Dengue virus infection.
Tryptase and chymase levels in Dengue patients
We also measured the tryptase and chymase levels in plasma
collected from the Dengue patients (day 0) and controls by ELISA.
Plasma tryptase levels increased significantly in DHF and DSS
compared with DF, febrile illness, and healthy subjects (Fig. 3). In
contrast, the chymase levels were increased significantly in DSS
compared with DF, DHF, febrile illness, and healthy subjects
(Fig. 3). We next measured the plasma levels of tryptase and
chymase in DHF (n=21) and DSS (n=27) patients during the
admission period and found that the protease levels had gradually
declined by days 2 and 4 to a comparable level with those of DF,
febrile illness, and healthy subjects (chymase DF: 4.862 ng/ml,
DHF: 6.762.4 ng/ml, febrile illness: 6.262 ng/ml, healthy
subjects: 4.561.3 ng/ml, tryptase DF: 7.464.3 ng/ml, febrile
illness: 6.762.6 ng/ml, healthy subjects: 7.763.4 ng/ml) (Fig. 2).
These results suggested that mast cells and mast cell-derived
proteases participated in the severe form of Dengue virus infection.
IL-4, IL-9, and IL-17 levels in Dengue patients
As IL-9 has been reported as a T cell-derived mast cell growth
factor [32–34] and more recently, is implicated as a Th17-derived
cytokine that can contribute to inflammatory diseases, we
investigated the involvement of IL-9 and IL-17 in Dengue virus
infection. The levels of IL-9 and IL-17 in Dengue patients on day
0, and those in blood samples collected from febrile illness and
healthy subjects were measured by ELISA. The analysis showed
that IL-9 and IL-17 levels were significantly increased in DHF and
DSS compared with those in DF, febrile illness, and healthy
subjects (Figs. 4A and B).
Although these results suggested that IL-9 and IL-17 participate
in Dengue virus infection, IL-9 may act additively or synergisti-
cally with other factors, such as other Th2 cytokines, to induce
optimal mast cell responses. To examine the possibility that Th2
cytokines affect mast cell responses in Dengue virus infection, IL-4
levels were also examined in plasma from Dengue patients and
control groups (Fig. 4C). We found comparable levels of IL-4
between Dengue patients and control groups, suggesting the
involvement of IL-9 and -17 in Dengue virus infection.
In-vitro production of VEGF in mast cells
To investigate if Dengue virus induces VEGF production from
mast cells, the in-vitro production of VEGF in the human mast cell
lines KU812 and HMC-1 was examined. KU812 and HMC-1
cells were inoculated with Dengue virus in the presence of either
human Dengue virus-immune or normal human serum, and
VEGF levels in the culture medium were assessed 24 h after viral
inoculation. As the antibody-dependent enhancement of infection
in KU812 and HMC-1 cells was observed at 1:1,000 and 1:10,000
dilutions of human Dengue virus-immune serum in preliminary
experiments (data not shown), a 1:1,000 dilution was used in the
in-vitro experiments in this study.
The production of VEGF was observed in both KU812 and
HMC-1 cells after exposure to Dengue virus in the presence
human Dengue virus-immune serum, however, VEGF levels were
higher in KU812 cells (Table 2). No significant increase of VEGF
Role of Mast Cells in Dengue Shock Syndrome
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human serum (1:1,000 final dilution) or when UV-inactivated
Dengue virus was inoculated with human Dengue virus immune
or normal human serum. In addition, no VEGF production by
KU812 and HMC-1 cells was observed after mock-infection with
human Dengue immune or normal human serum. These results
suggested the importance of antibody to Dengue virus for mast cell
secretion of VEGF in vitro.
As it is known that KU812 and HMC-1 cells are permissive to
Dengue virus infection when the virus is inoculated together with
human Dengue immune serum [20], the antibody-dependent
infection of KU812 cells with Dengue virus was examined by
immunofluorescence analysis in the presence and absence of
human Dengue immune serum 24 h after the inoculation. Positive
immunofluorescence was only observed in cells infected in the
presence of human Dengue virus-immune serum, suggesting the
Figure 1. Plasma levels of VEGF, and sVEGFR-1 and -2 in Dengue patients and control groups. Plasma levels of VEGF (A), and sVEGFR-1 (B)
and -2 (C) were examined for Dengue patients (DF, DHF, and DSS) on admission and for control subjects (febrile illness and healthy subjects) by ELISA.
VEGF *p,0.01 (DHF and DSS versus DF, febrile illness or healthy subjects), sVEGFR-1 *p,0.01 (DSS versus DF, DHF, febrile illness or healthy subjects),
sVEGFR-2 *p,0.01 (DHF and DSS versus DF, febrile illness or healthy subjects). Representative results from three independent experiments are shown.
doi:10.1371/journal.pntd.0001505.g001
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www.plosntds.org 5 February 2012 | Volume 6 | Issue 2 | e1505Figure 2. Plasma levels of VEGF, sVEGFRs, tryptase, and chymase in Dengue patients during the admission period. Plasma levels of
VEGF, sVEGFR-1 and -2, tryptase, and chymase were examined for Dengue patients with DHF (A) and DSS (B) by ELISA. VEGF in DHF *p,0.01 (day 4
versus day 0 and 2) and DSS *p,0.01 (day 2 and 4 versus day 0), sVEGFR-1 in DSS *p,0.01 (day 2 and 4 versus day 0), sVEGFR-2 in DHF *p,0.01 (day
4 versus day 0 and 2) and DSS *p,0.01 (day 4 versus day 0 and 2), tryptase in DHF *p,0.01 (day 4 versus day 0 and 2) and DSS *p,0.01 (day 4 versus
day 0 and 2), chymase in DSS *p,0.01 (day 4 versus day 0 and 2). Results are representative of two independent experiments.
doi:10.1371/journal.pntd.0001505.g002
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determine the role of IL-9 in VEGF production by mast cells, KU-
812 and HMC-1 cells were inoculated with Dengue virus and
human Dengue virus-immune serum (1:1,000 final dilution) in the
presence and absence of IL-9. Although a low level of VEGF
production by KU-812 and HMC-1 cells was observed without
IL-9, VEGF levels were significantly increased in the presence of
IL-9 (Table 3). The effect of IL-9 on VEGF production by KU812
and HMC-1 cells was not observed in the presence of normal
human serum (data not shown). Taken together, these findings
suggested the possibility that Dengue virus induces VEGF
secretion from human mast cells during infection, and that IL-9
supports the production of VEGF in mast cells.
Discussion
Recently, Srikiatkhachorn et al. [48] compared the plasma
levels of VEGF-A and sVEFGR-1 and -2 between DHF and DF
patients, and found a rise of VEGF-A and decline of sVEGFR-2
levels in DHF patients, with the severity of plasma leakage
inversely correlating with sVEGFR-2 levels. These findings
seemed to be consistent with our present results that VEGF and
sVEGFR-2 were significantly increased and reduced, respectively,
in DHF and DSS patients. Although the reason why sVEGFR-2
levels are decreased in DHF and DSS patients is not clear, as
VEGF binding to VEGFR-2 on endothelial cells results in receptor
phosphorylation, changes in endothelial cell morphology and
proliferation, and maintenance of physiological condition of blood
vessels, decreased sVEGFR-2 levels in severe Dengue patients
might represent the dysfunction of homeostasis in vascular
endothelial cells and correlate with increased plasma leakage
[49]. We additionally observed a significant increase of sVEGFR-1
levels in DSS patients, which suggests that activation of
monocytes/macrophages by Dengue virus leads to increased
expression of soluble and surface VEGFR-1 on cells during severe
Dengue infection, as was previously reported [49].
Regarding the relationship between VEGF level and severity of
Dengue virus infection, Tseng et al. [3] observed the elevation of
Figure 3. Plasma levels of tryptase and chymase in Dengue patients and control groups. Plasma levels of tryptase (A) and chymase (B)
were examined for Dengue patients (DF, DHF, and DSS) on admission and for control groups (febrile illness and healthy subjects) by ELISA. Tryptase
*p,0.01 (DHF and DSS versus DF, febrile illness or healthy subjects), and Chymase *p,0.01 (DSS versus DF, DHF, febrile illness or healthy subjects).
Representative results from three independent experiments are shown.
doi:10.1371/journal.pntd.0001505.g003
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phases of Dengue infection, as compared to DF patients and
healthy controls. In a study of a pediatric population with DHF,
Srikiatkhachorn et al. [6] also detected a rise in circulating VEGF
in the early febrile and defervescent stages of Dengue infection, but
not during the later convalescent stage. However, subsequent
studies reported contradictory findings, as increased circulating
VEGF concentrations were not observed during the early febrile
and toxic stages in DHF, but lower VEGF concentrations were
detected in patients with more severe Dengue infection [50–52].
Several underlying reasons may explain these differences, such as
poor study design, small sample size, and the lack of a
standardized collection methodology and storage of blood samples
used for the measurement of VEGF. In addition, VEGF is also
expressed at low levels in a wide variety of normal adult human
and animal tissues, and at higher levels in a few selected sites,
Figure 4. Plasma levels of IL-9, -17, and -4 in Dengue patients and control groups. Plasma levels of IL-9 (A), -17 (B), and -4 (C) were
examined for Dengue patients (DF, DHF and DSS) and control groups (febrile illness and healthy subjects) by ELISA. IL-9, *p,0.01 (DHF and DSS
versus DF, febrile illness and healthy subjects), IL-17, *p,0.01 (DHF and DSS versus DF, febrile illness and healthy subjects). Representative results
from three independent experiments are shown.
doi:10.1371/journal.pntd.0001505.g004
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prostatic epithelium and semen, and certain epithelial cells of the
adrenal cortex and lung [53]. Dovrak et al. [54] reported that
VEGF is substantially overexpressed at both the mRNA and
protein levels in a high percentage of malignant animal and
human tumors, as well as in many transformed cell lines. Thus,
studies of VEGF production by mast cells during Dengue virus
infection are complicated by these alternate sources of VEGF in
human and animals, and may affect circulating VEGF levels.
Incubation of KU812 and HMC-1 cells with Dengue virus in
the presence of human Dengue virus-immune serum resulted in
enhanced VEGF production, which was not observed when UV-
inactivated Dengue virus was incubated with human Dengue
virus-immune serum or when Dengue virus was used alone to
infect KU812 cells (Table 2). As the permissive infection of
Dengue virus was observed in KU812 cells (Fig. 5), these findings
suggest the critical importance of antibodies to Dengue virus for
VEGF production by highly infected mast cells and indicate that
infected mast cells can secrete VEGF without stimulation through
FceRI. Our results appear consistent with the findings that
Dengue virus infection induces the production of chemokines by
human mast cells without stimulation of FceRI in the presence of
human Dengue immune serum [22]. Brown et al. [55] reported
that FccRII plays a dominant role in antibody-enhanced Dengue
virus infection of the human mast cell lines HMC-1 and KU812,
and in the associated CCL5 release. In studies of DHF epidemics,
Halstead et al. [56] and Guzman et al. [57] demonstrated that
secondary infection is the most important host risk factor for DHF.
Boesiger et al. and Gru ¨tzkau et al. [46,47] reported that mouse
and human mast cells produce and secrete VPF/VEGF, and
release VEGF upon stimulation through FceRI or after challenge
with chemical mast cell activators. Notably, the FceRI-dependent
secretion of VEGF by either mouse or human mast cells is
significantly increased in cells that have undergone upregulation of
FceRI surface expression by preincubation with IgE. As Koraka
[58] reported that Dengue virus-specific IgE levels were
significantly higher in DHF and DSS patients compared to those
in DF and non-Dengue patients, FceRI may be important for mast
cell activation via IgE antibody in Dengue virus infection.
However, we did not determine whether the patient sera collected
in the present contained IgE antibody against Dengue virus. To
clarify the importance of FceRI for VEGF production by mast
cells in Dengue virus infection, further studies are needed.
High levels of VEGF in culture supernatants were detected
when KU812 and HMC-1 cells were cultured in the presence of
IL-9 (Table 3). As IL-9 enhances the survival of mast cells and
induces their production of proinflammatory cytokines, including
Th1 and Th2 cytokines [59], it is possible that IL-9 primes HMC-
1 and KU812 cells in vitro to respond to Dengue virus infection by
promoting VEGF production. To evaluate the contribution of IL-
9 and IL-17 to Dengue virus infection, we measured the plasma
levels of these two cytokines in Dengue patients and found that
both IL-9 and IL-17 were significantly increased in DHF and DSS
compared with DF, febrile illness and healthy subjects. These
findings suggest that Th9 and Th17 cells contribute to the
inflammatory response to severe Dengue virus infection. It is
possible that IL-9 may act additively or synergistically with other
factors, such as additional Th2 cytokines, to induce the mast cell
response observed in this study. However, as the level of IL-4 was
not increased in the plasma of Dengue patients, our findings
suggest the independent involvement of IL-9 secreted by Th2 cells
in Dengue virus infection. Recently, IL-9-producing cells have
been described as a new subset of the T helper cell population
separate from Th2 that produces IL-9 in large quantities and
contributes uniquely to immune responses [60,61]. This cell
population has been named ‘Th9’, and IL-9 secreted by T cells,
particularly Th9 cells, may regulate chronic allergic inflammation
[62]. Moreover, IL-9 has been recently proposed to function as a
Th17-derived cytokine that contributes to inflammatory diseases
[36].
Tryptase and chymase levels were significantly increased in
DHF and DSS, and DSS, respectively, on admission compared
with DF, febrile illness, and healthy subjects (Fig. 3). However, 2–4
days after admission, the levels of these proteases had returned to
similar levels with the other patient groups (Fig. 2). These findings
support the concept that mast cells and mast cell degranulation
play important roles in the pathogenesis of DHF/DSS and might
be suitable targets for new therapies and prevention of Dengue
infection. However, it is presently unclear whether Dengue virus
infection in mast cells directly induces chymase and tryptase
production and secretion. Recently, Kitamura-Inenaga et al. [63]
reported that encephalomyocarditis virus infection results in mast
cell chymase and tryptase production in vivo, and additionally, viral
infections have been shown to cause the accumulation of mast cells
in the nasal mucosa during the first days of a symptomatic,
naturally acquired respiratory infection [64]. However, the
relevance and underlying mechanisms of mast cell infection and
activation in the setting of viral infections remain to be
characterized in detail.
Immunocytohistochemical studies in human tissues have
identified two mast cell phenotypes distinguishable by their neutral
protease content, namely the ‘mast cell-tryptase’ (MCT) pheno-
type and the ‘mast cell-tryptase-chymase’ (MCTC) phenotype
[65]. MCT appears to be associated with immune system-related
mast cells that play a primary role in host defenses and are
preferentially located at mucosal surfaces. MCT mast cells are
increased in number in areas of T lymphocyte infiltration and in
allergic disease, and are reduced in number in acquired and
chronic immunodeficiency syndromes [65]. In contrast, the
MCTC phenotype appears to be associated with non-immune
system-related mast cells that primarily function in angiogenesis
and tissue remodeling, rather than immunologic protection, and
are found predominantly in submucosal and connective tissues. In
addition, MCTC mast cells are not increased in numbers in areas
Table 2. VEGF production by KU812 and HMC-1 cells
exposed to Dengue virus.
Cell line Serum DV UDV C3/36
a C48/80
b (ng/ml)
KU812 HDIS 4.260.9* 0.460.3 0.460.1 7.560.8*
KU812 NHS 0.560.2 0.460.2 0.460.1 7.360.4*
HMC-1 HDIS 2.360.4* 0.560.2 0.460.1 4.660.4*
HMC-1 NHS 0.560.1 0.460.1 0.360.2 4.260.7*
KU812 and HMC-1 cells were inoculated with Dengue virus-2 (DV) or UV-
irradiated Dengue virus-2 (UDV) in the presence of human Dengue-immune
serum (HDIS, 1:1000 final dilution) or normal human serum (NHS, 1:1000 final
dilution), and VEGF levels in culture supernatants were then examined 24 h
later. Significant VEGF production was not observed when KU812 and HMC-1
cells were infected with DV alone (data not shown).
HDIS in KU812*p,0.01 (HDIS and C48/80 versus UDV or C3/36), NHS in KU812
*p,0.01 (C48/80 versus DV, UDV or C3/36), HDIS in HMC-1 *p,0.01 (DV versus
UDV, C3/36 or C48/80), NHS in HMC-1 *p,0.01 (C48/80 versus DV, UDV, or C3/
36).
a: C3/36 medium alone served as a negative control.
b: Activation of mast cells with C48/80 (300 mg/ml) was used as a positive
control.
doi:10.1371/journal.pntd.0001505.t002
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in immunodeficiency syndromes [65]. In the present study, a
significant increase of chymase was observed in the plasma of DSS
patients as compared with those of DF, DHF, and the control
group, suggesting the possibility that MCTC mast cells contribute
to the pathogenesis of severe forms of Dengue virus infection.
However, further study is needed to clarify the roles of tryptase
and chymase in severe Dengue virus infection.
Concerning the ability of mediators produced by mast cells
other than VEGF to activate endothelial cells, King et al. [22]
reported that Dengue virus plus Dengue virus-specific antibody
treatment results in selective production of the T-cell chemoat-
tractants RANTES, MIP-1a, and MIP-1b by KU812 and HMC-1
human mast cell-basophil lines. In addition, Brown et al. [66]
demonstrated that antibody-enhanced Dengue virus infection of
primary human cord blood-derived mast cells (CBMCs) and
Figure 5. Immunofluorescence staining of Dengue virus-infected KU812 cells. KU812 cells inoculated with a combination of Dengue virus-2
and human Dengue virus-immune or normal human serum were harvested 24 h post-infection. The harvested cells were incubated with mouse anti-
Dengue virus monoclonal antibody 1B7 (30) or isotype-matched mouse IgG2a antibody (negative control) as a primary antibody. Anti-mouse IgG
labeled with FITC was used as a secondary antibody. (A)–(C) KU812 cells inoculated with a combination of Dengue virus and human Dengue virus-
immune serum (A 1:1000, 640; B 1:10000 final dilution, 640) or normal human serum (C 1:1000 final dilution, 620). (D)–(E) KU812 cells inoculated
with a combination of UV-inactivated Dengue virus and human Dengue virus-immune serum (D 1:1000, 640) or human Dengue immune serum
alone (E 1:1000, 620). Similar results were obtained from two additional experiments.
doi:10.1371/journal.pntd.0001505.g005
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which subsequently activate human endothelial cells. St. John et
al. [67] reported that the response to mast cell activation involves
the de novo transcription of cytokines, including TNF-a and IFN-a,
and chemokines, such as CCL5, CXCL12, and CX3CL1, which
are well characterized to recruit immune effector cells, including
cytotoxic lymphocytes, to sites of peripheral inflammation.
In conclusion, we found that mast cells and mast cell-derived
mediators, namely VEGF, and the mast cell-specific proteases
tryptase and chymase participate in the development of severe
forms of Dengue virus infection, which is accompanied by elevated
circulating levels of IL-9 and -17. As tryptase and chymase are
known as selective markers of non-immune system-related
activation of mast cells in submucosal and connective tissues,
these two proteases, particularly chymase, might serve as good
predictive markers of Dengue disease severity.
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